Related Experiment Video
Updated: Aug 14, 2025
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Therapeutic potential of paeoniflorin in atherosclerosis: A cellular action and mechanism-based perspective
Wei Yu1,2, Iqra Ilyas3, Xuerui Hu4
1School of Materials Science and Engineering, Hefei University of Technology, Hefei, Anhui, China.
Insights
Paeoniflorin, derived from the traditional medicine *P. lactiflora*, shows promise in treating atherosclerotic cardiovascular disease (ASCVD). This review explores its anti-atherosclerosis effects and molecular mechanisms, highlighting its potential as a therapeutic agent.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Immunology
Background:
- Atherosclerotic cardiovascular disease (ASCVD) incidence, prevalence, and mortality are rising globally.
- Atherosclerosis is a chronic inflammatory disease involving immune dysfunction.
- Traditional Chinese medicine *P. lactiflora* Pall. has a long history of use for various ailments.
Purpose of the Study:
- To review the therapeutic effects of paeoniflorin, a bioactive compound from *P. lactiflora* Pall., against atherosclerosis.
- To elucidate the molecular mechanisms underlying paeoniflorin's protective effects, focusing on inflammation and immune pathways.
- To discuss the potential of paeoniflorin as a therapeutic agent for ASCVD.
Main Methods:
- Comprehensive literature review of studies on paeoniflorin and atherosclerosis.
- Analysis of paeoniflorin's effects on vascular endothelial cells, smooth muscle cells, monocytes, macrophages, platelets, and mast cells.
- Examination of inflammation and immune-related pathways involved in atherosclerosis.
Main Results:
- Paeoniflorin exhibits multiple protective effects against atherosclerosis.
- It modulates inflammation and immune responses in various cell types relevant to atherosclerosis.
- The compound targets key molecular pathways implicated in the disease process.
Conclusions:
- Paeoniflorin demonstrates significant potential as a therapeutic agent for atherosclerosis and its complications.
- Further research and clinical translation are warranted to explore its full therapeutic value.
- Paeoniflorin offers a promising avenue for novel cardiovascular disease treatments.
Abstract:
Epidemiological studies have shown that the incidence, prevalence and mortality of atherosclerotic cardiovascular disease (ASCVD) are increasing globally. Atherosclerosis is characterized as a chronic inflammatory disease which involves inflammation and immune dysfunction. P. lactiflora Pall. is a plant origin traditional medicine that has been widely used for the treatment of various diseases for more than a millennium in China, Japan and Korean. Paeoniflorin is a bioactive monomer extracted from P. lactiflora Pall. with anti-atherosclerosis effects. In this article, we comprehensively reviewed the potential therapeutic effects and molecular mechanism whereby paeoniflorin protects against atherosclerosis from the unique angle of inflammation and immune-related pathway dysfunction in vascular endothelial cells, smooth muscle cells, monocytes, macrophages, platelets and mast cells. Paeoniflorin, with multiple protective effects in atherosclerosis, has the potential to be used as a promising therapeutic agent for the treatment of atherosclerosis and its complications. We conclude with a detailed discussion of the challenges and future perspective of paeoniflorin in translational cardiovascular medicine.
More Related Videos
Related Concept Videos
01:26Atherosclerosis III: Management
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:27Peripheral Artery Disease III: Interprofessional Care
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...